Gilead Sciences vs Novo Nordisk
Gilead Sciences (GILD), health care, and Novo Nordisk (NVO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Gilead Sciences is worth $210.7B on the stock market and Novo Nordisk $179B: Gilead Sciences is valued at 18% more. Gilead Sciences's operating margin in its latest fiscal year was 34.0% and Novo Nordisk's 41.3%. Over the past year Gilead Sciences's share price has moved +31.8% and Novo Nordisk's -12.5%.
Key facts
- Gilead Sciences market value
- $210.7B
- Novo Nordisk market value
- $179B
- Novo Nordisk P/E
- 10.3
- Gilead Sciences revenue
- $29.4BFY to 2025-12-31
- Novo Nordisk revenue
- $45.9BFY to 2025-12-31
- Superinvestors holding both
- 2
Market values as of .
| Measure | Gilead Sciences | Novo Nordisk |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $210.7Bhigher | $179Blower |
| Revenue | $29.4Blower | $45.9Bhigher |
| Earnings | $8.5Blower | $15.2Bhigher |
| Employees | 17,000lower | 68,794higher |
| Total assets | $59Blower | $80.6Bhigher |
| Valuation | ||
| P/E | — | 10.3 |
| P/S | 7.2higher | 3.9lower |
| P/B | 16.2 | — |
| Dividend yield | 1.94% | — |
| Profitability | ||
| Operating margin | 34.0%lower | 41.3%higher |
| Balance sheet | ||
| Net assets | $22.7Blower | $28.8Bhigher |
| Total liabilities | $36.4Blower | $51.8Bhigher |
| Total debt | $24.9Bhigher | $19.4Blower |
| Cash on hand | $7.6Bhigher | $3.9Blower |
| Price change | ||
| Today | +1.39%higher | -2.37%lower |
| 1 year | +31.8%higher | -12.5%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (2)
- Dodge & Cox team1.7% / 0.4%
- Jim Simons (1938–2024)0.4% / 0.2%
Gilead Sciences only (8)
- Brandon Haley0.9%
- Josef Lakonishok0.7%
- John Rogers0.3%
- Fred DiSanto0.3%
- Steve Cohen0.3%
- Ken Griffin0.3%
- David Shaw (founder)0.2%
- Ray Dalio (founder)0.2%
Novo Nordisk only (6)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Gilead Sciences / Novo Nordisk). Who owns GILD · Who owns NVO
More on Gilead Sciences
Further comparisons
Gilead Sciences against its closest peers
Novo Nordisk against its closest peers
Learn
Questions and answers
Which is bigger, Gilead Sciences or Novo Nordisk?
By market value, Gilead Sciences is the larger: $210.7B against $179B for Novo Nordisk. By revenue in its latest fiscal year, Novo Nordisk is the larger: $45.9B against $29.4B for Gilead Sciences.
Which has the higher operating margin?
Novo Nordisk: 41.3%, against 34.0% for Gilead Sciences. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Gilead Sciences: $24.9B, against $19.4B for Novo Nordisk. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Gilead Sciences and Novo Nordisk?
In their latest 13F filings, Dodge & Cox team and Jim Simons (1938–2024) hold both.
Cite this page
Funkfolio, “Gilead Sciences vs Novo Nordisk”, data as of 17 November 2026. https://funkfolio.com/compare/gild-vs-nvo
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.